The study focuses on pregnant women with von Willebrand Disease (VWD), a condition where blood does not clot properly. During pregnancy, some women may not have enough of the blood-clotting proteins, von Willebrand factor (VWF) or factor VIII (FVIII), which could lead to bleeding issues during delivery. The study aims to find out how much these protein levels need to be increased using a treatment called Wilate to ensure safe delivery and recovery.

• The study involves taking Wilate during delivery and for a short period after.
• It will assess the safety and effectiveness of this treatment.
• The study requires participation until delivery and may involve follow-up visits.

This study is only for women with certain types of VWD and specific blood protein levels. It excludes individuals with other bleeding disorders, liver or kidney diseases, or those under 18. Participants must give written consent before the 39th week of pregnancy.